10 Kidney Cancer 1 1 0 17 17 1264 http://clinicaltrials.dfhcc.harvard.edu/trials/1264 Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery RATIONALE: Sunitinib and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib or sorafenib after surgery may kill any tumor cells that remain after surgery. It is not yet known whether sunitinib is more effective than sorafenib or placebo in treating kidney cancer. PURPOSE: This randomized phase III trial is studying sunitinib to see how well it works compared to sorafenib or placebo in treating patients with kidney cancer that has been removed by surgery. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer Phase 3 10 http://clinicaltrials.dfhcc.harvard.edu/trials/10 Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma The purpose of this study is to determine if certain features of tumor specimens sampled prior to therapy can predict for the likelihood of responding to everolimus. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer Phase 2 145 http://clinicaltrials.dfhcc.harvard.edu/trials/145 Phase 2 Study in Patients With MiT Tumors This is a multi-center, single arm intended to evaluate the anti-tumor effect of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors. MiT tumors include clear cell sarcoma, alveolar soft parts sarcoma, and translocation associated renal cell carcinoma. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma Phase 2 188 http://clinicaltrials.dfhcc.harvard.edu/trials/188 Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma The purpose of this research study is to find out the effects (good and bad) the study treatment has on participants and their cancer. Temsirolimus has been approved by the Food and Drug Administration (FDA) in the treatment of renal cell carcinoma. Avastin has been approved by the FDA for other types of cancers but not renal cell carcinoma. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer Phase 2 381 http://clinicaltrials.dfhcc.harvard.edu/trials/381 Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer The purpose of this study is to learn if PET scanning can predict the degree of tumor shrinkage with the study drug RAD001 in subjects who have advanced renal cancer. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer Phase 2 396 http://clinicaltrials.dfhcc.harvard.edu/trials/396 Bevacizumab, Sorafenib, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab and sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor. Temsirolimus and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving different combinations of bevacizumab, sorafenib, and temsirolimus may be more effective than bevacizumab alone in treating metastatic kidney cancer. PURPOSE: This randomized phase II trial is studying different combinations of bevacizumab, temsirolimus, and sorafenib to see how well they work compared with bevacizumab alone in treating patients with metastatic kidney cancer. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer Phase 2 457 http://clinicaltrials.dfhcc.harvard.edu/trials/457 Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF The main purpose of this study is to test the safety of the dendritic cell/tumor fusion study vaccine in combination with a laboratory-made agent called Granulocyte Macrophage Colony Stimulating Factor (GM-CSF). Another purpose is to determine the type and severity of any side effects associated with this study vaccine. GM-CSF is similar to a substance in the body that stimulates the production of white blood cells. To create the study vaccine, cells will be removed from the participants tumor and fused with dendritic cells which are obtained from the participants blood. Dendritic cells are responsible for immune responses to "foreign" substances that enter the body. Animal studies have shown that these fused cells can stimulate powerful anti-tumor responses. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer Phase 1/Phase 2 65 http://clinicaltrials.dfhcc.harvard.edu/trials/65 A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated. Recruiting 24 Prostate Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/24-prostate-cancer 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 1 124 http://clinicaltrials.dfhcc.harvard.edu/trials/124 Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GC1008, a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in previously treated patients with locally advanced or metastatic renal cell carcinoma or malignant melanoma. Recruiting 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer Phase 1 333 http://clinicaltrials.dfhcc.harvard.edu/trials/333 Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC) The purpose of this study is to assess magnetic resonance imaging (MRI) as a tool to track tumor growth for renal cell carcinoma while the participant is receiving clinical treatment therapy with sunitinib. An MRI is a sophisticated type of scan that uses powerful magnets to make clearer images or to focus on detailed medical information in the participants abdomen and pelvis. This imaging done for this study will use the ASL MRI technique that allows us to see blood flow changes which possibly may indicated tumor growth. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer N/A 1285 http://clinicaltrials.dfhcc.harvard.edu/trials/1285 Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma The purpose of this study is to assess magnetic resonance imaging (MRI) as a tool to track tumor growth for renal cell carcinoma while participants are on clinical treatment therapy of sunitinib and AMG386. An MRI is a type of scan that uses powerful magnets to make clearer images or to focus on detailed medical information in the abdomen and pelvis. The imaging done for this study will use the arterial spin labeling (ASL) MRI technique that allows us to see blood flow changes which possibly may indicate changes in tumor growth. Participants will be on a clinical trial for the treatment. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer N/A 1198 http://clinicaltrials.dfhcc.harvard.edu/trials/1198 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib This is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in progression free survival (PFS) and evaluate the safety and tolerability of AMG 386 in combination with sorafenib in the treatment of subjects with advanced clear cell carcinoma of the kidney. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer 1222 http://clinicaltrials.dfhcc.harvard.edu/trials/1222 Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer 1227 http://clinicaltrials.dfhcc.harvard.edu/trials/1227 Study of MDX-1411 Given Every 14 Days With Pre-Medications to Subjects With Clear Cell Kidney Cancer. To determine the highest and safest tolerated dose of MDX-1411 for the treatment of clear cell renal cell carcinoma (Kidney cancer). Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer 1228 http://clinicaltrials.dfhcc.harvard.edu/trials/1228 Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma This study is being conducted to provide a direct comparison of the efficacy, safety and tolerability for pazopanib and sunitinib (SUTENT) Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer 1255 http://clinicaltrials.dfhcc.harvard.edu/trials/1255 AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib This phase 2 study is an open-label, single arm, multi-center study to determine the safety and tolerability of AMG 386 in combination with sunitinib in the treatment of subjects with metastatic renal cell carcinoma. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer 1308 http://clinicaltrials.dfhcc.harvard.edu/trials/1308 Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer